[New] A landmark Lancet study forecasts 39.1 million deaths directly caused by drug-resistant infections between 2025 and 2050, rounding to three infections every minute.
The Hawk News
[New] In the Americas, U.S. output rose 5.2% in 2025 but is now projected at just 0.9% for 2026 and is being influenced by fading tariff effects and growing generic and biosimilar competition.
pharmexec
[New] By 2026, we expect to see AI-powered platforms like Exscientia playing a crucial role in drug discovery.
Innovation Hub Live
[New] Personalized medicine is projected to account for over 40% of all new drug approvals by 2028.
Innovation Hub Live
[New] If a company pledges to invest in U.S. drug manufacturing in the coming years, its tariff rate will fall to 20%.
Edge and Odds -
[New] Rising prevalence of drug-resistant infections and government-led monitoring initiatives drive a steady 5.47% CAGR through 2035.
Yahoo Finance
[New] Donald Trump is threatening 100% tariffs on pharmaceutical companies that have not struck deals to lower US drug prices.
The Guardian
[New] Bad news for the pharmaceutical sector, as reports suggest the US administration could be following through on Trump's threats from last year to impose 100% tariff rates on branded medicines as soon as today.
The Chartered Institute of Export & International Trade
[New] With Americans used to paying the highest drug prices in the world, the implementation of most-favored-nation drug pricing agreements and other strategies will remain key points of discussion through 2026.
Akin Gump Strauss Hauer & Feld LLP
[New] From OpenAI quietly cutting products to redirect compute, to pharma doubling down on AI-driven drug discovery, to lawsuits that could redefine how AI companies train their models, today's developments signal something bigger.
Tech Startups - Tech News, Tech Trends & Startup Fundin
[New] The remarks signal how Washington is increasingly treating drug discovery as geopolitical infrastructure, raising the likelihood that pharma partnerships, licensing deals and supply chains tied to China will face growing policy scrutiny.
MM+M - Medical Marketing and Media
By 2030, 80% of pharmaceutical companies are projected to partner with TechBios, leveraging agentic AI and quantum computing to reduce R&D costs and failure rates.
IDC
The cumulative effect is a streamlined clinical data package for biosimilar applications, which the FDA estimates could save developers up to 50% of PK study costs - potentially as much as $20 million per program - by avoiding unnecessary bridging studies.
Skadden, Arps, Slate, Meagher & Flom LLP
With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability.
Oncology Practice Management
Pharmaceutical manufacturers may need to balance partnerships with Chinese innovators against rising supply chain and security risks, while also absorbing a greater share of early-stage research and innovation costs to sustain global competitiveness.
PwC
Leading Drug Therapy: Antipsychotic drugs are projected to dominate due to their established clinical efficacy, widespread adoption, and functional integration across pediatric and adolescent care settings, holding approximately 42% share in 2026.
Persistence Market Research
Without urgent action, the WHO warns, drug-resistant infections could claim 39 million lives worldwide by 2050 and impose an annual economic burden of up to $412bn (£307bn).
The Guardian
The approaching patent cliff-projected to expose as much as $300 billion in annual drug sales to loss of exclusivity by 2032 - is expected to keep pharmaceutical M&A activity active in 2026, but not necessarily drive a dramatic year-over-year spike in deal volume or size.
Pharmaceutical Commerce
Investigational New Drug - enabling studies are expected to begin in H1 2026.
GlobeNewswire
Last updated: 07 April 2026
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
